Nevertheless, other studies have shown that immunoreactive and serum hPL were identified exclusively in patients with breast carcinomas and that none were detected in benign or normal cases [4,18,19], which led to a proposal that hPL could potentially serve as a tumor biomarker for breast cancer [6]. This evidence concerns the gene LGALS1 and breast carcinoma.